BSE Live
Apr 17, 16:01Prev. Close
268.65
Open Price
258.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Profit & Loss account of Auro Laboratories (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 19.12 | 52.70 | 52.26 | 50.44 | 52.93 | |
| Less: Excise/Sevice Tax/Other Levies | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue From Operations [Net] | 19.12 | 52.70 | 52.26 | 50.44 | 52.93 | |
| Total Operating Revenues | 19.40 | 53.64 | 52.89 | 50.87 | 54.25 | |
| Other Income | 0.66 | 1.50 | 0.94 | 1.09 | 0.76 | |
| Total Revenue | 20.05 | 55.14 | 53.84 | 51.96 | 55.01 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 5.06 | 29.04 | 37.30 | 33.74 | 27.43 | |
| Purchase Of Stock-In Trade | 0.02 | 0.00 | 0.00 | 0.02 | 0.21 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | 4.13 | -2.48 | -1.61 | -0.98 | 0.91 | |
| Employee Benefit Expenses | 2.47 | 5.14 | 4.72 | 6.24 | 6.04 | |
| Finance Costs | 1.08 | 0.74 | 0.81 | 0.83 | 0.46 | |
| Depreciation And Amortisation Expenses | 1.10 | 1.09 | 1.07 | 1.02 | 1.04 | |
| Other Expenses | 4.32 | 11.26 | 8.08 | 7.22 | 8.43 | |
| Total Expenses | 18.17 | 44.79 | 50.39 | 48.08 | 44.50 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 1.88 | 10.35 | 3.45 | 3.87 | 10.51 | |
| Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | 1.88 | 10.35 | 3.45 | 3.87 | 10.51 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 0.10 | 2.74 | 1.00 | 1.07 | 3.20 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | -0.06 | -0.19 | 0.00 | -0.04 | 0.12 | |
| Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | 0.04 | 2.55 | 1.00 | 1.03 | 3.33 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 1.84 | 7.79 | 2.44 | 2.84 | 7.18 | |
| Profit/Loss From Continuing Operations | 1.84 | 7.79 | 2.44 | 2.84 | 7.18 | |
| Profit/Loss For The Period | 1.84 | 7.79 | 2.44 | 2.84 | 7.18 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 2.95 | 12.50 | 3.92 | 4.56 | 11.52 | |
| Diluted EPS (Rs.) | 2.95 | 12.50 | 3.92 | 4.56 | 11.52 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 0.00 | 14.16 | 25.02 | 19.76 | 11.32 | |
| Indigenous Raw Materials | 5.06 | 14.88 | 12.29 | 13.98 | 15.50 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Equity Dividend Rate (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
10.02.2026
Auro Labs Standalone December 2025 Net Sales at Rs 9.39 crore, up 207.49% Y-o-Y
13.11.2025
Auro Labs Standalone September 2025 Net Sales at Rs 8.84 crore, up 184.94% Y-o-Y
10.06.2025
Auro Labs Standalone March 2025 Net Sales at Rs 7.40 crore, down 38.65% Y-o-Y
13.11.2024
Auro Labs Standalone September 2024 Net Sales at Rs 3.10 crore, down 76.88% Y-o-Y
10.02.2026
Auro Labs Standalone December 2025 Net Sales at Rs 9.39 crore, up 207.49% Y-o-Y
13.11.2025
Auro Labs Standalone September 2025 Net Sales at Rs 8.84 crore, up 184.94% Y-o-Y
10.06.2025
Auro Labs Standalone March 2025 Net Sales at Rs 7.40 crore, down 38.65% Y-o-Y
13.11.2024
Auro Labs Standalone September 2024 Net Sales at Rs 3.10 crore, down 76.88% Y-o-Y
13.04.2026
13.04.2026
10.04.2026
09.04.2026
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth